Why the study?
DMD has large unmet medical needs with limited treatment options, warranting clear rationale for accelerated approval of AAV microdystrophin gene therapies.
Can microdystrophin expression serve as a surrogate endpoint for accelerated approval of AAV microdystrophin gene therapy in Duchenne Muscular Dystrophy?
Can microdystrophin expression serve as a surrogate endpoint for accelerated approval of AAV microdystrophin gene therapy in Duchenne Muscular Dystrophy?
Microdystrophin expression is proposed as a viable surrogate endpoint to facilitate accelerated approval of gene therapies for Duchenne Muscular Dystrophy.
Answers are grounded in this paper and cite their sources.
Supports surrogate endpoint use for accelerated DMD gene therapy approval; leaves open need for outcome validation before clinical adoption.
gene and is characterized by progressive muscle degeneration that results in loss of function and early death due to respiratory and/or cardiac failure. Although limited treatment options are available, some for only small subsets of the patient population, DMD remains a disease with large unmet medical needs. The adeno-associated virus (AAV) vector is the leading gene delivery system for addressing genetic neuromuscular diseases. Since the gene encoding the full-length dystrophin protein exceeds the packaging capacity of a single AAV vector, gene replacement therapy based on AAV-delivery of shortened, yet, functional microdystrophin genes has emerged as a promising treatment. This article seeks to explain the rationale for use of the accelerated approval pathway to advance AAV microdystrophin gene therapy for DMD. Specifically, we provide support for the use of microdystrophin expression as a surrogate endpoint that could be used in clinical trials to support accelerated approval.
No takes yet. Share an insight, caveat, or question.
Chamberlain et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: